{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:04Z","timestamp":1761630784492,"version":"3.37.3"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent years have seen a growing interest in <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content> within the scientific community, healthcare providers and industries, coupled with great advances in the understanding of the molecular and genetic basis and the natural history of the disease. Several disease\u2010modifying agents targeting the immune\u2010mediated response and bile\u2010acid therapies are at different stages of development, some with promising results. A new drug, obeticholic acid, has been recently registered in the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> and Europe as a second\u2010line treatment in refractory <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>. International cohort studies have highlighted a disease heterogeneity, and so the need to provide patients with a more personalised management based on their risk of disease progression. Major challenges remain the development of surrogate endpoints in clinical trials acceptable to regulatory authorities, in a disease with a relatively low rate of events; and the development of clinical tools for patient's risk stratification and selection of those with greatest potential benefit from second\u2010line therapies.<\/jats:p>","DOI":"10.1111\/liv.13353","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T10:00:30Z","timestamp":1490868030000},"page":"503-505","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of <scp>PBC<\/scp>\u2014A step forward"],"prefix":"10.1111","volume":"37","author":[{"given":"Marco","family":"Carbone","sequence":"first","affiliation":[{"name":"Program for Autoimmune Liver Diseases International Center for Digestive Health Department of Medicine and Surgery University of Milan Bicocca  Milan Italy"},{"name":"Academic Department of Medical Genetics University of Cambridge  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-1998","authenticated-orcid":false,"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Program for Autoimmune Liver Diseases International Center for Digestive Health Department of Medicine and Surgery University of Milan Bicocca  Milan Italy"},{"name":"Division of Rheumatology, Allergy and Clinical Immunology University of California at Davis School of Medicine  Davis CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13294"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.12.005"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.003"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.09.020"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28359"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28017"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.061"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344270"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.05.023"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.12.005"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:37:06Z","timestamp":1695548226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/liv.13353"],"URL":"https:\/\/doi.org\/10.1111\/liv.13353","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"type":"print","value":"1478-3223"},{"type":"electronic","value":"1478-3231"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}